| scholarly article | Q13442814 |
| P2093 | author name string | Zhigang Yu | |
| Sunil Nepal | |||
| Charles Frost | |||
| Wonkyung Byon | |||
| Jessie Wang | |||
| Yu Chen Barrett | |||
| Frank Lacreta | |||
| Andrew Shenker | |||
| Rebecca A Boyd | |||
| Alan Schuster | |||
| Rogelio Mosqueda-Garcia | |||
| P2860 | cites work | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 |
| Structure-based design of novel potent nonpeptide thrombin inhibitors | Q27638874 | ||
| Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...] | Q27648707 | ||
| Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits | Q28219397 | ||
| Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor | Q28272154 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Factor Xa or thrombin: is factor Xa a better target? | Q33291055 | ||
| Limitations of traditional anticoagulants | Q33362181 | ||
| Warfarin therapy: evolving strategies in anticoagulation. | Q33535795 | ||
| Apixaban or enoxaparin for thromboprophylaxis after knee replacement | Q34018819 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial | Q34102430 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after hip replacement | Q34156023 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| The "HemoQuant" test: a specific and quantitative determination of heme (hemoglobin) in feces and other materials. | Q34265161 | ||
| Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects | Q34285711 | ||
| Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate | Q34590281 | ||
| Assays for measuring rivaroxaban: their suitability and limitations | Q37789142 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors | Q44465978 | ||
| Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis | Q44854409 | ||
| Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits | Q46468984 | ||
| Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study | Q46550059 | ||
| Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies | Q46722053 | ||
| Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. | Q50357077 | ||
| General derivation of the equation for time to reach a certain fraction of steady state. | Q52434488 | ||
| The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. | Q53229008 | ||
| Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics | Q73289567 | ||
| Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy) | Q74019320 | ||
| Factor Xa--a promising target for drug development | Q77826627 | ||
| Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay | Q82070566 | ||
| Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma | Q82961588 | ||
| Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls | Q83080848 | ||
| Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays | Q85193723 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| apixaban | Q414462 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 776-786 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects | |
| P478 | volume | 76 |
| Q54965803 | A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge. |
| Q40090376 | A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics |
| Q34531991 | A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban |
| Q50794115 | Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. |
| Q36836396 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial |
| Q26780328 | Apixaban and oral implications |
| Q38566808 | Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation |
| Q92028447 | Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review |
| Q38960858 | Apixaban: A Review in Venous Thromboembolism |
| Q38107180 | Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation |
| Q47764609 | Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban |
| Q37639007 | Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation |
| Q37037385 | Direct oral anticoagulant drug level testing in clinical practice: A single institution experience |
| Q90749273 | Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update |
| Q90348789 | Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care |
| Q90211829 | Drug-Drug Interactions with Direct Oral Anticoagulants |
| Q53218072 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. |
| Q37353441 | Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects |
| Q35557449 | Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor |
| Q89532369 | Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients |
| Q90593427 | Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis |
| Q33647367 | Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study |
| Q35666219 | Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban |
| Q50056281 | Efficacy of non-specific hemostatic agents for reversal of prophylactic apixaban levels. |
| Q26743614 | Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants |
| Q41125977 | Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. |
| Q42387444 | Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism |
| Q34993935 | Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis |
| Q92297441 | Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution |
| Q41627248 | Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System®: In Vitro and Ex Vivo Studies |
| Q34554473 | Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban |
| Q93377864 | Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects |
| Q35164902 | Global assays and the management of oral anticoagulation |
| Q90103174 | Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study |
| Q28079697 | Implications of apixaban for dental treatments |
| Q51739901 | Initial Apixaban Dosing in Patients with Atrial Fibrillation. |
| Q38205947 | Interpretation of coagulation test results under direct oral anticoagulants |
| Q38956699 | Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review |
| Q34206252 | Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. |
| Q39266311 | Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice |
| Q28257188 | Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system |
| Q26766303 | Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy |
| Q38953781 | Measurement and reversal of the direct oral anticoagulants |
| Q40744632 | Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. |
| Q35154142 | Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. |
| Q45865979 | Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology |
| Q34086522 | Measurement of rivaroxaban and apixaban in serum samples of patients |
| Q93092143 | Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation |
| Q34413003 | Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery |
| Q88670340 | Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients |
| Q26771728 | Monitoring anticoagulant therapy with new oral agents |
| Q59268547 | Multimodal assessment of non-specific hemostatic agents for apixaban reversal |
| Q38878032 | Newer Oral Anticoagulants: Stroke Prevention and Pitfalls |
| Q35674404 | Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations |
| Q38826151 | Overview of direct oral anticoagulant therapy reversal |
| Q38386660 | Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation |
| Q38777127 | Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis |
| Q48952027 | Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. |
| Q28078967 | Pharmacology of anticoagulants used in the treatment of venous thromboembolism |
| Q64977733 | Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. |
| Q33729811 | Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism |
| Q33854667 | Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. |
| Q41947735 | Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect |
| Q53663177 | Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval. |
| Q48599279 | Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. |
| Q26764874 | Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date |
| Q93024841 | Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report |
| Q37388373 | Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects |
| Q48163723 | Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol |
| Q96588890 | Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real life study |
| Q92576182 | Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world |
| Q37328158 | The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study. |
| Q37669187 | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| Q28539517 | Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria |
| Q92977571 | Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways |
| Q64988900 | Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. |
| Q37073792 | Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH |
| Q38655960 | Who, when, and how to reverse non-vitamin K oral anticoagulants |
| Q50959098 | [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?] |
| Q88460453 | [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks] |
Search more.